Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicentre phase 2 trial of oral decitabine-tetrahydrouridine (NDec) in sickle cell disease
2020-003485-39Phase 2Active
- Sponsor
- Novo Nordisk
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of decitabine + tetrahydrouridine in sickle cell disease (SCD) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Change in total haemoglobin. Started May 2022; status: active.
02
Drugs
decitabine + tetrahydrouridine
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2020-003485-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003485-39.